
**PROFIT GUIDANCE FOR THE SECOND HALF AND FULL YEAR
ENDED 31 DECEMBER 2020**

The Board of Directors (the “**Board**”) of OUE Lippo Healthcare Limited (“**Company**”, together with its subsidiaries, “**Group**”) wishes to advise shareholders that the Group is expected to report a net loss for the second half ended 31 December 2020 (“**2H2020**”) and the full year ended 31 December 2020 (“**FY2020**”) based on a preliminary assessment of the Group’s unaudited consolidated financial results for 2H2020 and FY2020.

The ongoing Covid-19 (Coronavirus Disease 2019) pandemic continues to disrupt the normal operations of the global economy. As a result, businesses and asset values across many regions and countries have been adversely impacted in an unprecedented manner. Given the current pandemic situation and the fact that the Group operates businesses and owns assets and has investments across several countries, there have been material repercussions on the financial performance of the Group.

Therefore, the Group is expected to record provisions and impairments to the carrying value of its (a) investment in associates and joint ventures (including its investment in First Real Estate Investment Trust); (b) investment properties; (c) investment properties under development; and (d) property, plant and equipment, resulting in significant loss in 2H2020 and FY2020.

The Group is in the process of finalising its unaudited financial results for 2H2020 and FY2020. Further details of the Group’s financial results will be disclosed when the Company announces its unaudited financial results for 2H2020 and FY2020, on or around 23 February 2021.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
15 January 2021

This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 Web: www.ouelh.com